Table 3.
The percentage of women who reported specific adverse events during clinical trials of hormonal contraceptive methods.
| Adverse Event | Contraceptive | Adverse Event Frequency (%) | Sample size | Publication |
|---|---|---|---|---|
| SORE BREASTS | COC | 8.3 | 2837 | Yasmin (2017) |
| COC | 3.8 | 2501 | NuvaRing® (2017) | |
| IUS | 8.5† | 5091 | Mirena (2017) | |
| Injection | 2.8 | >3900 | Depo-Provera (2019) | |
| NAUSEA/ VOMITING | COC | 4.5 | 2837 | Yasmin (2017) |
| COC | 16.3 | 1723 | Ortho Tri-Cyclen Lo (2019) | |
| Injection | 3.3 | >3900 | Depo-Provera (2019) | |
| Patch | 16.6 | 3322 | ||
| Vaginal Ring | 5.9 | 2501 | NuvaRing® (2017) | |
| CHANGES IN PREMENSTRUAL SYNDROME | COC | 13.2 | 2837 | Yasmin (2017) |
| VAGINAL DISCHARGE | IUS | 14.9* | 5091 | Mirena (2017) |
| Vaginal Ring | 5.7 | 2501 | NuvaRing® (2017) | |
| ALTERATION OF MENSTRUAL BLEEDING PATTERNS | IUS | 31.9* | 5091 | Mirena (2017) |
| VULVOVAGINITIS | IUS | 10.5* | 5091 | Mirena (2017) |
| BACK PAIN | IUS | 7.9* | 5091 | Mirena (2017) |
| DYSMENORRHEA | Vaginal Ring | 3.5 | 2501 | NuvaRing® (2017) |
| COC | 6.4* | 5091 | Mirena (2017) | |
| Injection | 1.7 | >3900 | Depo-Provera (2019) | |
| Patch | 7.8 | 3322 | Ortho Evra (2010) |